Butyl chloroformate

Acute Toxicity: other routes

Administrative data

Endpoint:

acute toxicity: other routes

Type of information:

experimental study

Adequacy of study:

supporting study

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: Non-GLP non-guideline, available as unpublished report, limitations restrictions in design and/or reporting.

Data source

Reference

Reference 1

Reference Type:

study report

Title:

Unnamed

Year:

1970

Report date:

1970

Reference 2

Reference Type:

other: English translation (summary)

Title:

Unnamed

Year:

2005

Report date:

2005

Materials and methods

Principles of method if other than guideline:

According to BASF-internal standard: Five Kisslegg mice per sex per dose were exposed to the test substance, dissolved in an aqueous emulsion with Tragacanth, via intraperitoneal injection. After an observation period of 14 days animals were necropsied.

GLP compliance:

no

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

Butyl chloroformate

EC Number:

209-750-5

EC Name:

Butyl chloroformate

Cas Number:

592-34-7

Molecular formula:

C5H9ClO2

IUPAC Name:

butyl carbonochloridate

Details on test material:

- Name of the test substance used in the study report: n-Butylchlorkohlensäureester; Chloroformic acid butyl ester
- Physical state: liquid

Test animals

Species:

mouse

Strain:

other: Kisslegg mice

Sex:

male/female

Administration / exposure

Route of administration:

intraperitoneal

Vehicle:

other: aqueous emulsion with Tragacanth

Details on exposure:

The test concentrations used were 0.1, 0.5 and 1% (V/V).

Doses:

6.4, 8, 10, 25, 50 (0.1% substance preparation), 12.5, 25 (0.5% substance preparation), 50 mm3/kg (1% test substance preparation)

No. of animals per sex per dose:

5

Control animals:

no

Details on study design:

- Duration of observation period following administration: 14 days
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs

Results and discussion

Effect levels

Effect levels 1

Sex:

male/female

Dose descriptor:

LD50

Effect level:

< 13 mg/kg bw

Based on:

other: 0.5% test substance preparation

Remarks on result:

other: original value: <12.5 mm3/kg

Effect levels 2

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 53 mg/kg bw

Based on:

other: 0.1% test substance preparation

Remarks on result:

other: original value: >50 mm3/kg

Mortality:

0.1% test substance preparation:
- 6.4, 8 and 10 mm3/kg: no deaths after 14 days;
- 25 and 50 mm3/kg: 1/10 after 14 days;

0.5% test substance preparation:
- 12.5 mm3/kg: 8/10 after 14 days;
- 25 mm3/kg: 9/10 after 14 days;

1% test substance preparation:
- 50 mm3/kg: 10/10 after 14 days

Clinical signs:

- 1% and 0.5% test substance preparation: Immediately after the injection restlessness, long legged gait, sunken flanks, rapid breathing and stretching was observed. During the observation period the surviving animals showed prone position, dyspnea, heavily ruffled fur, sticky eyes, slight apathy, slight trembling, and quiet behavior. From day 13 no effects were observed.
- 0.1% test substance preparation: (50 and 25 cmm/kg): Immediately after the injection rapid breathing, delayed movements of the extremities. After 5 hours quiet behavior, dyspnea and closed eyes were observed. After six days no effects were observed.
- 0.1% test substance preparation: (10, 8, and 6.4 cmm/kg): Immediately after the injection rapid breathing, delayed movements of the extremities, restlessness, long legged gait, and stretching was observed. The next day rapid breathing and ruffled fur was observed. After five days no effects were observed.

Gross pathology:

Adhesions in the abdominal cavity were observed.